3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 2
2
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
138
Carcinoma, Non-Small-Cell Lung
109
Prostatic Neoplasms
51
Lung Neoplasms
31
Neoplasm Metastasis
20
Stomach Neoplasms
18
Parkinson Disease 4, Autosomal Dominant Lewy Body
17
Nasopharyngeal Carcinoma
16
Neoplasms
15
Squamous Cell Carcinoma of Head and Neck
14
Esophageal Neoplasms
11
Head and Neck Neoplasms
8
Urinary Bladder Neoplasms
7
HER2-positive Breast Cancer
7
Esophageal Squamous Cell Carcinoma
7
Ovarian Neoplasms
6
Carcinoma
6
Adenocarcinoma
6
Inflammatory Breast Neoplasms
5
Fallopian Tube Neoplasms
5
Endometrial Neoplasms
5
Carcinoma, Squamous Cell
5
Adenocarcinoma of Lung
5
Triple Negative Breast Neoplasms
4
Recurrence
4
Carcinoma, Transitional Cell
4
Adenocarcinoma Of Esophagus
4
Primary Breast Cancer
3
Carcinoma, Ovarian Epithelial
3
Adenocarcinoma, Bronchiolo-Alveolar
3
Interventions
Cisplatin
4
Paclitaxel
3
Vinblastine
2
Methotrexate
2
Gemcitabine
2
Doxorubicin
2
Carboplatin
2
cabozantinib
1
avelumab
1
Specimen Handling
1
Ramucirumab
1
Platinum
1
Magnetic Resonance Spectroscopy
1
Immunoglobulin G
1
Fentanyl
1
Docetaxel
1
Disulfides
1
Bevacizumab
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Urethral Neoplasms
×
Docetaxel
×
Clear all
NCT02426125
2023-08-21
RANGE
Eli Lilly and Company
Phase 3
Completed
530 enrolled
22 charts